RGNX (Regenxbio) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNX Regenxbio Inc RGNX
59 GF Score
Price $9.20
GF Value $15.49
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Regenxbio FFO per Share?

FFO per Share only applies to REITs.

RGNX
59GF Score
Regenxbio Inc RGNX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (RGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be undervalued. The current stock price of $9.20 is trading 40.6% below its estimated GF Value™ of $15.49. GuruFocus considers Regenxbio to be Possible Value Trap.

Key valuation signals for RGNX:

  • FFO per Share:
  • GF Value™: $15.49 vs. price of $9.20 (40.6% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the RGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
59GF Score

Get the complete analysis for RGNX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.20
Price
$15.49
GF Value